Overview

BATTLE Program: Sorafenib in Patients With NSCLC

Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
Primary Objective: - To determine the 8 week progression-free survival rate (i.e. disease control rate) in patients with advanced non-small cell lung cancer (NSCLC) who have failed at least one prior chemotherapy regimen. Secondary Objective: The secondary objectives of this study will be to: - Determine the overall response rate - Determine the overall survival - Determine the time to disease progression - Assess the safety/toxicity of the study treatment - Assess biomarker modulation in the tumor tissue and serum samples from the treatment. - Assess plasma and intra-tumor concentrations of study treatment
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Bayer
United States Department of Defense
Treatments:
Niacinamide
Sorafenib